BeOne Medicines Ltd. (ONC) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $310.00. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ONC = $63.14 (-79.6% from the current price, the stock appears overvalued). Analyst consensus target is ONC = $410 (+32.2% upside).
Valuation: ONC trades at a trailing Price-to-Earnings (P/E) of 177.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.1.
Financials: revenue is $5.3B, +56.3%/yr average growth. Net income is $287M, growing at +75.8%/yr. Net profit margin is 5.4% (thin). Gross margin is 87.5% (+123.6 pp trend).
Balance sheet: total debt is $2.0B against $4.4B equity (Debt-to-Equity (D/E) ratio 0.46, conservative). Current ratio is 3.41 (strong liquidity). Debt-to-assets is 24.4%. Total assets: $8.2B.
Analyst outlook: 12 / 13 analysts rate ONC as buy (92%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 31/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 83/100 (Pass), Moat 80/100 (Pass), Future 100/100 (Pass), Income 45/100 (Partial).
